heat shock protein family E (Hsp10) member 1 pseudogene 26Genealiases: []
Q-omics provides the consensus-scored HSPE1P26 profile across patient tissues and cancer cell-line models. HSPE1P26 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, HSPE1P26 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, HSPE1P26 RNA expression shows 14,349 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight PAAD, BRCA, and THYM as cancer lineages where HSPE1P26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPE1P26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPE1P26 survival associations across molecular data types. HSPE1P26 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPE1P26 RNA expression–survival associations across cancer types. High HSPE1P26 expression shows unfavorable associations in PAAD, UCEC and THCA, but favorable associations in BRCA, BLCA and ACC. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for HSPE1P26 RNA expression.
This table summarizes HSPE1P26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HSPE1P26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPE1P26 shows lower tumor expression in BRCA and KIRP and higher tumor expression in KIRP. The BRCA box plot shows higher HSPE1P26 RNA expression in normal versus tumor tissue (log2 FC = −0.321, t-test p = .019).
This table shows molecular features associated with HSPE1P26 in patient tissues and cancer cell lines. In patient samples, HSPE1P26 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
